Its efficacy was demonstrated in the PROFILE 1014 phase III randomized trial, which showed a significant progression-free survival (PFS) benefit with crizotinib compared to platinum-based chemotherapy (10.9 vs. 7.0 months; HR 0.45, 95% CI 0.35–0.60) in patients with metastatic ALK-rearranged NSCLC (4, 5). This evidence concerns the gene ALK and non-small cell lung carcinoma.